Table 2.
Method validation using serum spiked with a mock mixture of twelve disaccharide standardsa.
| m/z | Theo. (%) | Expt'l (%) | Diff. (%) | |
|---|---|---|---|---|
| IV-A | 378.11− | 8.3 | 8.3 | 0.0 |
| III-A | 458.11− | 8.3 | 9.2 | 0.9 |
| II-A | 458.11− | 8.3 | 8.6 | 0.3 |
| I-A | 268.72− | 8.3 | 7.5 | −0.8 |
| IV-S | 416.11− | 8.3 | 8.1 | −0.2 |
| III-S | 247.72− | 8.3 | 8.2 | −0.1 |
| II-S | 247.72− | 8.3 | 8.3 | 0.0 |
| I-S | 191.53− | 8.3 | 8.3 | 0.0 |
| I-H | 247.72− | 8.3 | 8.8 | 0.5 |
| II-H | 416.11− | 8.3 | 8.4 | 0.1 |
| III-H | 416.11− | 8.3 | 9.2 | 0.9 |
| IV-H | 336.31− | 8.3 | 7.2 | −1.1 |
a
The purification and compositional analysis method was validated using serum matrix spiked with a mock mixture of 10 μM each of 12 heparin/HS-derived disaccharide standards.